Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX EXVIERA

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX EXVIERA: AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).